- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00052559
Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer
A Phase I Study Of The Antiangiogenic Agent Bevacizumab In Combination With 5-Fluourouracil And External Beam Radiation Therapy In Rectal Cancer
Studieoversikt
Status
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of a vascular endothelial growth factor (VEGF) neutralizing antibody, bevacizumab, when administered concurrently with 5-fluorouracil (5-FU) and external beam radiation therapy (EBRT) in patients with clinical stage T3 or T4 rectal cancer prior to surgery.
II. To obtain preliminary data of the pathological response rate after preoperative therapy.
III. To obtain preliminary data regarding progression free survival, local control, and overall survival.
IV. To obtain preliminary data of the changes in the angiogenic profile of rectal cancer induced by this therapy.
OUTLINE: This is a multicenter, dose-escalation study of bevacizumab.
Patients receive bevacizumab IV over 30-90 minutes on day 1 (courses 1-4). Beginning with course 2, patients also receive fluorouracil IV continuously on days 1-14 and undergo external beam radiotherapy on days 1-5 and 8-12. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo surgery 7 weeks after completion of chemoradiotherapy.
Cohorts of 6 patients receive escalating doses of bevacizumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 20 additional patients are treated at the MTD.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually for 2 years.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Massachusetts General Hospital Cancer Center
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Duke University Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically confirmed primary adenocarcinoma of the rectum that begins within 15 cm of the anal verge as determined by sigmoidoscopy and/or colonoscopy
Clinical T3 or T4 tumors as determined by the following features:
- Tethered or fixed tumor on physical exam
- cT3, cT4, or N+ disease must be confirmed by an endorectal ultrasound or surface coil MRI
- There must be no evidence of metastatic disease as confirmed by physical examination, chest radiograph, and abdominal/pelvic CT scan
- ECOG performance status 0, 1, 2 (Karnofsky >= 70%)
- Life expectancy of greater than 2 years
- Leukocytes >= 3,000/ul
- Absolute neutrophil count >= 1,500/ul
- Platelets >= 100,000/ul
- Total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal
- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- The effects of bevacizumab on the developing human fetus are unknown; for this reason and because radiation therapy and 5-FU agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
- Patients with no known HIV or HIV risk factors will be eligible for this study without HIV testing
Exclusion Criteria:
- Patients with a "concurrently active" second malignancy other than non- melanoma skin cancers or in situ cervical cancer are excluded; patients are not considered to have a "concurrently active" malignancy if they have completed therapy and considered by their physician to be at less than 30% risk of relapse at a minimum of 5 years after all therapy
Prior Treatment:
- No prior treatment for this malignancy
- No prior history of pelvic irradiation
- No prior history of 5-FU-based therapy for any malignancy
- No prior treatment with bevacizumab
- Patients must not be receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition bevacizumab or other agents used in study
Bevacizumab - Specific exclusion criteria:
- History or evidence upon physical examination of CNS disease (e.g., primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of stroke
- Serious, non-healing wound, ulcer, or bone fracture
- Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, history of myocardial infarction, unstable angina within 12 months), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 1 year prior to Day 0
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study; biopsies (other than rectal cancer) within 7 days prior to Day 0; placement of a vascular access device within 7 days prior to Day 0
- Arterial thromboembolic events within previous 12 months including transient ischemic attack, cerebrovascular accident, unstable angina, myocardial infarction, or clinically significant peripheral vascular disease. Vascular surgery, stenting or angioplasty within previous 12 months; no history of venous thromboembolic events that require continuation of therapeutic dose of anticoagulation
- Current or recent (within 10 days prior to Day 0) use of full-dose oral or parenteral anticoagulants or thrombolytic agents (except as required to maintain patency of preexisting, permanent indwelling IV catheters; for subjects receiving warfarin, international normalized ratio [INR] of < 1.5; appropriate use of heparin should be discussed with the Medical Monitor)
- Chronic, daily treatment with aspirin (> 325 mg/day) or nonsteroidal anti- inflammatory medications (of the kind known to inhibit platelet function at doses used to treat chronic inflammatory diseases)
- Presence of bleeding diathesis or coagulopathy
- Active infection requiring parenteral antibiotics on Day 0
- Proteinuria at baseline or clinically significant impairment of renal function
- Subjects unexpectedly discovered to have >= 1+ proteinuria during screening should undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate < 1 gram protein/24 hr to allow participation in the study
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because bevacizumab, radiation therapy, and 5-FU have potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with bevacizumab, breastfeeding should be discontinued if the mother is treated with bevacizumab; these potential risks may also apply to other agents used in this study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Treatment (bevacizumab, fluorouracil, radiation therapy)
Patients receive bevacizumab IV over 30-90 minutes on day 1 (courses 1-4). Beginning with course 2, patients also receive fluorouracil IV continuously on days 1-14 and undergo external beam radiotherapy on days 1-5 and 8-12. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients undergo surgery 7 weeks after completion of chemoradiotherapy. Cohorts of 6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 20 additional patients are treated at the MTD. |
Korrelative studier
Gitt IV
Andre navn:
Gitt IV
Andre navn:
Å bli operert
Gjennomgå ekstern strålebehandling
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Maximum tolerated dose of bevacizumab when administered concurrently with 5-fluorouracil (5-FU) and external beam radiation therapy (EBRT) in patients with cT3 and T4 rectal cancer prior to surgery
Tidsramme: 29 days
|
29 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Total overlevelse
Tidsramme: Inntil 5 år
|
Inntil 5 år
|
|
Lokal kontroll
Tidsramme: Inntil 5 år
|
Inntil 5 år
|
|
Pathological response rate after preoperative bevacizumab, 5-FU, EBRT, and surgery
Tidsramme: Up to 5 years
|
Up to 5 years
|
|
Progression-free survival
Tidsramme: From protocol entry until documented progression of disease or death from any cause, assessed up to 5 years
|
The progression-free survival curve will be estimated using the Kaplan-Meier methods.
|
From protocol entry until documented progression of disease or death from any cause, assessed up to 5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Christopher Willett, Duke University
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer
- Neoplasmer etter nettsted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Tarmsykdommer
- Intestinale neoplasmer
- Rektale sykdommer
- Kolorektale neoplasmer
- Rektale neoplasmer
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Angiogenese-hemmere
- Angiogenesemodulerende midler
- Vekststoffer
- Veksthemmere
- Antistoffer
- Fluorouracil
- Immunoglobuliner
- Bevacizumab
- Antistoffer, monoklonale
- Antineoplastiske midler, immunologiske
Andre studie-ID-numre
- NCI-2012-02908
- U01CA062490 (U.S. NIH-stipend/kontrakt)
- U01CA099118 (U.S. NIH-stipend/kontrakt)
- 6042-05-7R1
- CDR0000258532
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Adenokarsinom i endetarmen
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aortic origin of the coronary artery (AAOCA)Italia
-
Maastricht University Medical CenterWingate Institute of NeurogastroenterologyRekrutteringfMRI | Transkutan vagus nervestimulering (tVNS) | Nucleus of the Solitary Tract (NTS)Nederland, Storbritannia
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Technical University of MunichInstitut für Allgemeine Pathologie und Pathologische Anatomie der TU... og andre samarbeidspartnereUkjentAssociation of Heterotopic Gastric Mucosa of the Cervical Esophagus and Globus SensationsTyskland
-
Xiros LtdHar ikke rekruttert ennåRiv av rotatormansjetten | Rotatormansjettskader | Rivner i rotatormansjetten | Rotator Cuff Tears of the Shoulder
-
Hospital Universitario La Pazspanish society of orthopedics and traumatologyFullførtRotator Cuff Tears of the ShoulderSpania
-
Tel-Aviv Sourasky Medical CenterRekrutteringPouchitis | Crhon's Disease Like of the PouchIsrael
-
Maxx Orthopedics IncRekrutteringBein tap | Periprotetiske brudd | Infeksjon | Aseptisk løsning | MCL - Medial Collateral Ligament Rupture of the KneeForente stater
-
Medical University of SilesiaFullførtSpirometrien; | The Strength of Respiratory Muscles - MIP, MEP; | Kyphose (Plurimeter-V) | Vinkelen på stammerotasjon i thoraxdelenPolen
-
Krankenhaus NordwestFullførtAvansert magekreft | Advanced Cancer of the Esophagogastric JunctionTyskland
Kliniske studier på laboratoriebiomarkøranalyse
-
Fondation LenvalTilbaketrukketCerebral pareseFrankrike
-
Liao Jian AnRekrutteringHode- og nakkekreftTaiwan
-
Progenity, Inc.FullførtDowns syndrom | Aneuploidi | DiGeorge syndrom | Turners syndrom | Klinefelters syndrom | Kromosomsletting | Edwards syndrom | Patau syndromForente stater
-
Tel-Aviv Sourasky Medical CenterUkjentBenmetastaser | Ortopedisk lidelse | Benneoplasma i hoften (diagnose) | Proksimal femoral metafyseal abnormitet
-
IRCCS Eugenio MedeaRekrutteringAutismespektrumforstyrrelse | Tidlig intervensjonItalia
-
Oregon Health and Science University4DMedicalPåmelding etter invitasjonLungesykdommer | KOLS | Luftveissykdom | DyspnéForente stater
-
IRCCS Eugenio MedeaRekrutteringCerebral parese | Ervervet hjerneskadeItalia
-
Duke UniversityTilbaketrukketAntikoagulasjons- og trombosepunkttest (AT-POCT)Forente stater
-
Modarres HospitalFullførtKomplikasjoner | Bildeveiledet biopsi | Nyre GlomerulusIran, den islamske republikken
-
University of California, Los AngelesFullførtHjertefeil | OvervektForente stater